<DOC>
	<DOCNO>NCT00697320</DOCNO>
	<brief_summary>This NON INTERVENTIONAL OBSERVATIONAL STUDY conduct Europe . The primary aim observe haemostatic efficacy NovoSeven® treatment routine practice German clinic . The observational study observe patient congenital haemophilia inhibitor coagulation factor VIII IX , acquire haemophilia , congenital FVII deficiency , Glanzmann 's thrombasthenia receive least one dose NovoSeven® treatment bleed episode prevention bleed undergoing surgery invasive procedure .</brief_summary>
	<brief_title>Observational Study Efficacy Safety NovoSeven® During `` Real-life '' Usage Germany</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Hemorrhagic Disorders</mesh_term>
	<mesh_term>Thrombasthenia</mesh_term>
	<criteria>Written inform consent obtain patient patient 's legally acceptable representative agree patient 's pseudonymised personal data transfer use scientific evaluation publication Due noninterventional observational character study , exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>